Laboratoires Théa

Laboratoires Théa is the leading independent European pharmaceutical company solely dedicated to ophthalmology and eye care products. Founded in 1994 by Henri Chibret (a fourth-generation member of a French ophthalmological dynasty with over 150 years of family history in eye care), the company researches, develops, manufactures, and commercializes a comprehensive range of ophthalmic solutions. Théa specializes in innovative drug delivery systems, new molecules for ophthalmic use, and the improvement of existing products through galenic development. The company is particularly renowned for pioneering preservative-free eye drop formulations and the ABAK® vial technology. Théa operates globally through a network of more than 35 independent subsidiaries and offices across Europe, North Africa, the Americas, and the Middle East, with products available in 75 countries worldwide. The company employs over 2,000 people and reported revenues of €970 million in 2024, making it a significant player in the global ophthalmology market. All manufacturing is conducted in Europe, with 60% of production in France, ensuring strict quality control and regulatory compliance. The company remains privately owned and controlled by the Chibret family, ensuring long-term independence and stability.